$0.20 Earnings Per Share Expected for Repligen Co. (RGEN) This Quarter

Wall Street analysts expect Repligen Co. (NASDAQ:RGEN) to report earnings per share of $0.20 for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.18. Repligen reported earnings of $0.17 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 17.6%. The business is expected to announce its next earnings results on Tuesday, May 14th.

On average, analysts expect that Repligen will report full-year earnings of $0.83 per share for the current year, with EPS estimates ranging from $0.81 to $0.84. For the next financial year, analysts expect that the business will report earnings of $1.00 per share, with EPS estimates ranging from $0.97 to $1.05. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Repligen.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.21. Repligen had a return on equity of 5.51% and a net margin of 8.56%. The firm had revenue of $51.90 million during the quarter, compared to analysts’ expectations of $50.27 million. During the same period last year, the firm posted $0.20 EPS. The business’s revenue was up 24.8% on a year-over-year basis.

A number of analysts recently issued reports on the company. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Tuesday, December 25th. BidaskClub downgraded Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $59.20.

In related news, CEO Anthony Hunt sold 7,475 shares of the company’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $59.01, for a total transaction of $441,099.75. Following the completion of the transaction, the chief executive officer now directly owns 250,132 shares in the company, valued at approximately $14,760,289.32. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Jon Snodgres sold 1,875 shares of the company’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $58.88, for a total value of $110,400.00. Following the transaction, the chief financial officer now owns 26,821 shares of the company’s stock, valued at $1,579,220.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,437 shares of company stock valued at $2,855,032. 1.40% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Huntington National Bank bought a new position in Repligen during the 1st quarter worth $25,000. First Hawaiian Bank acquired a new position in Repligen during the 4th quarter valued at about $28,000. Enlightenment Research LLC acquired a new position in Repligen during the 4th quarter valued at about $42,000. Parallel Advisors LLC boosted its stake in Repligen by 485.1% during the 4th quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 1,043 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in shares of Repligen by 16.8% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock worth $79,000 after buying an additional 214 shares during the last quarter. Hedge funds and other institutional investors own 91.18% of the company’s stock.

Shares of NASDAQ:RGEN traded up $0.56 during midday trading on Friday, hitting $54.76. The company had a trading volume of 215,626 shares, compared to its average volume of 285,515. Repligen has a 12 month low of $36.41 and a 12 month high of $70.50. The firm has a market capitalization of $2.41 billion, a P/E ratio of 75.01, a P/E/G ratio of 3.83 and a beta of 1.08.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Story: What is the Quick Ratio?

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.